-+ 0.00%
-+ 0.00%
-+ 0.00%

Tenaya to present new RIDGE-1 TN-401 gene therapy data at ASGCT 2026

PUBT·04/27/2026 12:31:44
Listen to the news
Tenaya to present new RIDGE-1 TN-401 gene therapy data at ASGCT 2026
  • Tenaya Therapeutics announced new interim clinical data from its RIDGE-1 Phase 1b/2 trial of TN-401 gene therapy in adults with PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
  • Results will be presented in a late-breaking oral session at ASGCT on May 15, 2026, covering one-year findings from the first dose cohort plus early data from the second cohort.
  • Update is set to include safety, biopsy, and efficacy readouts, positioning TN-401 as a potential disease-modifying approach that targets the underlying genetic cause.
  • Data package spans two dose levels, supporting assessment of risk-benefit and dose selection as program advances.
  • Tenaya also plans a webcast conference call around ASGCT to discuss the RIDGE-1 readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604270830PRIMZONEFULLFEED9707261) on April 27, 2026, and is solely responsible for the information contained therein.